BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22881866)

  • 1. Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library.
    Brožič P; Turk S; Adeniji AO; Konc J; Janežič D; Penning TM; Lanišnik Rižner T; Gobec S
    J Med Chem; 2012 Sep; 55(17):7417-24. PubMed ID: 22881866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3.
    Beranič N; Gobec S; Rižner TL
    Chem Biol Interact; 2011 May; 191(1-3):227-33. PubMed ID: 21182831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereospecific reduction of 5β-reduced steroids by human ketosteroid reductases of the AKR (aldo-keto reductase) superfamily: role of AKR1C1-AKR1C4 in the metabolism of testosterone and progesterone via the 5β-reductase pathway.
    Jin Y; Mesaros AC; Blair IA; Penning TM
    Biochem J; 2011 Jul; 437(1):53-61. PubMed ID: 21521174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3.
    Sinreih M; Sosič I; Beranič N; Turk S; Adeniji AO; Penning TM; Rižner TL; Gobec S
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5948-51. PubMed ID: 22897946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruthenium complexes as inhibitors of the aldo-keto reductases AKR1C1-1C3.
    Traven K; Sinreih M; Stojan J; Seršen S; Kljun J; Bezenšek J; Stanovnik B; Turel I; Rižner TL
    Chem Biol Interact; 2015 Jun; 234():349-59. PubMed ID: 25446855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tibolone metabolism in human liver is catalyzed by 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily.
    Steckelbroeck S; Oyesanmi B; Jin Y; Lee SH; Kloosterboer HJ; Penning TM
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1300-9. PubMed ID: 16339391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
    Adeniji AO; Twenter BM; Byrns MC; Jin Y; Chen M; Winkler JD; Penning TM
    J Med Chem; 2012 Mar; 55(5):2311-23. PubMed ID: 22263837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis.
    Hevir N; Vouk K; Sinkovec J; Ribič-Pucelj M; Rižner TL
    Chem Biol Interact; 2011 May; 191(1-3):217-26. PubMed ID: 21232532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
    Khanim F; Davies N; Veliça P; Hayden R; Ride J; Pararasa C; Chong MG; Gunther U; Veerapen N; Winn P; Farmer R; Trivier E; Rigoreau L; Drayson M; Bunce C
    Br J Cancer; 2014 Mar; 110(6):1506-16. PubMed ID: 24569460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinaldehyde is a substrate for human aldo-keto reductases of the 1C subfamily.
    Ruiz FX; Porté S; Gallego O; Moro A; Ardèvol A; Del Río-Espínola A; Rovira C; Farrés J; Parés X
    Biochem J; 2011 Dec; 440(3):335-44. PubMed ID: 21851338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New enzymatic assay for the AKR1C enzymes.
    Beranič N; Stefane B; Brus B; Gobec S; Rižner TL
    Chem Biol Interact; 2013 Feb; 202(1-3):204-9. PubMed ID: 23261716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human dehydrogenase/reductase SDR family member 11 (DHRS11) and aldo-keto reductase 1C isoforms in comparison: Substrate and reaction specificity in the reduction of 11-keto-C
    Endo S; Morikawa Y; Kudo Y; Suenami K; Matsunaga T; Ikari A; Hara A
    J Steroid Biochem Mol Biol; 2020 May; 199():105586. PubMed ID: 31926269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
    Byrns MC; Steckelbroeck S; Penning TM
    Biochem Pharmacol; 2008 Jan; 75(2):484-93. PubMed ID: 17950253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones.
    Penning TM; Burczynski ME; Jez JM; Hung CF; Lin HK; Ma H; Moore M; Palackal N; Ratnam K
    Biochem J; 2000 Oct; 351(Pt 1):67-77. PubMed ID: 10998348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Porcine aldo-keto reductase 1C subfamily members AKR1C1 and AKR1C4: Substrate specificity, inhibitor sensitivity and activators.
    Endo S; Morikawa Y; Matsunaga T; Hara A; Nishinaka T
    J Steroid Biochem Mol Biol; 2022 Jul; 221():106113. PubMed ID: 35398259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3.
    Stefane B; Brozic P; Vehovc M; Rizner TL; Gobec S
    Eur J Med Chem; 2009 Jun; 44(6):2563-71. PubMed ID: 19237229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.
    Byrns MC; Jin Y; Penning TM
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):95-104. PubMed ID: 21087665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism of the synthetic progestogen norethynodrel by human ketosteroid reductases of the aldo-keto reductase superfamily.
    Jin Y; Duan L; Chen M; Penning TM; Kloosterboer HJ
    J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):139-44. PubMed ID: 22210085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.
    Liedtke AJ; Adeniji AO; Chen M; Byrns MC; Jin Y; Christianson DW; Marnett LJ; Penning TM
    J Med Chem; 2013 Mar; 56(6):2429-46. PubMed ID: 23432095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
    Byrns MC; Penning TM
    Chem Biol Interact; 2009 Mar; 178(1-3):221-7. PubMed ID: 19010312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.